stoxline Quote Chart Rank Option Currency Glossary
Aceragen, Inc. (ACGN)
0.3849  0.005 (1.29%)    08-21 15:59
Open: 0.433
High: 0.3849
Volume: 52,509
Pre. Close: 0.38
Low: 0.3849
Market Cap: 3(M)
Technical analysis
2023-10-20 4:21:40 PM
Short term     
Mid term     
Targets 6-month :  0.75 1-year :  0.96
Resists First :  0.65 Second :  0.82
Pivot price 0.39
Supports First :  0.36 Second :  0.29
MAs MA(5) :  0.37 MA(20) :  0.41
MA(100) :  1.37 MA(250) :  3.98
MACD MACD :  -0.2 Signal :  -0.2
%K %D K(14,3) :  14.3 D(3) :  10.8
RSI RSI(14): 26.2
52-week High :  16 Low :  0.36
Price, MAs and Bollinger Bands

Price has closed below its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and BEARISH in mid-long term.
[ ACGN ] has closed above bottom band by 32.2%. Bollinger Bands are 86.9% narrower than normal. The narrow width of the bands suggests low volatility as compared to its normal range. The bands have been in this narrow range for 8 bars. This is a sign that the market may be about to initiate a new trend.

Stock Price Prediction
If tomorrow: Open lower Open higher
High: 0.38 - 0.38 0.38 - 0.38
Low: 0.37 - 0.38 0.38 - 0.38
Close: 0.38 - 0.38 0.38 - 0.38
Company Description

Aceragen, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of drugs for rare pulmonary and rheumatic diseases in the United States. Its clinical development pipeline includes ACG-701, which is in Phase 2 clinical trial for cystic fibrosis pulmonary exacerbations, as well as for melioidosis; and ACG-801 for farber disease. Aceragen, Inc. has a collaboration and option agreement with Scriptr Global, Inc. to identify, research, and develop gene therapy candidates for the treatment, palliation, diagnosis, or prevention of myotonic dystrophy type 1 and Friedreich's Ataxia. The company was formerly known as Idera Pharmaceuticals, Inc. and changed its name to Aceragen, Inc. in January 2023. Aceragen, Inc. was incorporated in 1989 and is headquartered in Exton, Pennsylvania.

Headline News

Mon, 07 Aug 2023
U.S. shares higher at close of trade; Dow Jones Industrial Average up 1.16% By - Canada

Mon, 07 Aug 2023
U.S. stocks higher at close of trade; Dow Jones Industrial Average up 1.16% By -

Wed, 26 Jul 2023
U.S. stocks mixed at close of trade; Dow Jones Industrial Average up 0.23% By -

Wed, 12 Jul 2023
Cash-strapped public company in Durham moves to liquidate. Will shareholders get anything? - The Business Journals

Fri, 05 May 2023
More layoffs in life sciences as Durham public company slashes workforce - The Business Journals

Sun, 10 Dec 2023

Financial Analysis
Price to Book Value:
P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly.
Price to Earnings:
PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS).
Discounted cash flow:
DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows.
Return on Assets:
ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit.
Return on Equity:
ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency.
Debt to Equity:
evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn.
Stock Basics & Statistics
Shares Out 8 (M)
Shares Float 3 (M)
Held by Insiders 69.7 (%)
Held by Institutions 2 (%)
Shares Short 131 (K)
Shares Short P.Month 96 (K)
Stock Financials
EPS -8.61
EPS Est Next Qtrly 0
EPS Est This Year 0
EPS Est Next Year 0
Book Value (p.s.) 2.7
Profit Margin 0 %
Operating Margin -311 %
Return on Assets (ttm) -26.3 %
Return on Equity (ttm) -98.7 %
Qtrly Rev. Growth 0 %
Gross Profit (p.s.) 0
Sales Per Share 0.87
EBITDA (p.s.) -2.71
Qtrly Earnings Growth 0 %
Operating Cash Flow -30 (M)
Levered Free Cash Flow 0 (M)
Stock Valuations
PE Ratio -0.05
PEG Ratio 0
Price to Book value 0.14
Price to Sales 0.43
Price to Cash Flow -0.11
Stock Dividends
Dividend 0
Forward Dividend 0
Dividend Yield 0%
Dividend Pay Date Invalid DateTime.
Ex-Dividend Date Invalid DateTime.

StockChart iOS

StoxlineLite iOS

StoxlineLite iOS

OptionCalc iOS

StockChart Android

StoxlineLite Android

StoxlinePro Android

OptionCalc Android